Stelios Papadopoulos - 07 Apr 2026 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Reporting relationship: Director
Issuer ticker: OVID
Reported as of: 07 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Apr 2026, 17:15:09 UTC
Prior SEC filing: 02 Mar 2026
Next SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Rona, Attorney-in-Fact

Key filing fact

Stelios Papadopoulos filed Form 4 for Ovid Therapeutics Inc. (OVID) on 09 Apr 2026.

Key facts

This page summarizes Stelios Papadopoulos's Form 4 filing for Ovid Therapeutics Inc. (OVID).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Apr 2026, 17:15.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001202098 Primary reporting owner

PAPADOPOULOS STELIOS

Relationship: Director
Address: C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, 14TH FLOOR, NEW YORK
Signature: /s/ Jeffrey Rona, Attorney-in-Fact
Signature date: 09 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OVID transaction

Common Stock

Award

Transaction value
Shares: +17,578
Change %: +8.8%
Price: $2.56^*
Shares after: 217,578
Date: 07 Apr 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.